Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : Lly save search
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for ...
Published: 2024-02-22 (Crawled : 12:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
Published: 2023-10-26 (Crawled : 00:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
bge-105 agonist treatment collaboration trial tirzepatide
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: -0.3%
H: 1.85%
C: -0.84%
cancer pharmaceuticals trial
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
Published: 2022-06-08 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: -1.26%
H: 1.8%
C: -0.71%
trial phase 2
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 2.14%
H: 0.69%
C: -0.26%
treatment phase 2 life science als
At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
phase 2 ulcerative colitis
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
heart positive trial
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.1%
H: 0.09%
C: -0.44%
RIGL | $1.06 -4.51% -4.72% 1.2M
|
Health Technology
|
| O: -0.26%
H: 8.84%
C: 8.44%
covid disease phase 2 infectious disease trial
Eli Lilly Hopes to Clear Runway for AD Drug with New Amyloid Data
Published: 2021-07-30 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
drug
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
plague
Clinical Catch-Up: July 5-9
Published: 2021-07-12 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
Clinical Catch-Up: June 14-18
Published: 2021-06-21 (Crawled : 16:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.25%
H: 2.13%
C: 1.63%
Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
Published: 2021-06-17 (Crawled : 01:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.22%
H: 1.28%
C: 0.88%
solid tumors trial
First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
Published: 2021-06-17 (Crawled : 01:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.22%
H: 1.28%
C: 0.88%
solid tumors trial
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
RIGL | $1.06 -4.51% -4.72% 1.2M
|
Health Technology
|
| O: 13.27%
H: 5.14%
C: 3.14%
covid phase 2 positive topline trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.